Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of combining venetoclax with Vyxeos
(CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not
responded to treatment.